BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 21824596)

  • 1. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer.
    Strobel O; Berens V; Hinz U; Hartwig W; Hackert T; Bergmann F; Debus J; Jäger D; Büchler MW; Werner J
    Surgery; 2012 Sep; 152(3 Suppl 1):S33-42. PubMed ID: 22770956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy].
    Rau HG; Wichmann MW; Wilkowski R; Heinemann V; Sackmann M; Helmberger T; Dühmke E; Schildberg FW
    Chirurg; 2002 Feb; 73(2):132-7. PubMed ID: 11974476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is celiac axis resection justified for T4 pancreatic body cancer?
    Yamamoto Y; Sakamoto Y; Ban D; Shimada K; Esaki M; Nara S; Kosuge T
    Surgery; 2012 Jan; 151(1):61-9. PubMed ID: 22088810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
    Eguchi H; Yamada D; Iwagami Y; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
    Dig Surg; 2018; 35(1):70-76. PubMed ID: 28482348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer.
    Helm J; Centeno BA; Coppola D; Melis M; Lloyd M; Park JY; Chen DT; Malafa MP
    Cancer; 2009 Sep; 115(18):4080-9. PubMed ID: 19626671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
    Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C
    Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection.
    Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laparoscopic resection of exocrine carcinoma in central and distal pancreas results in a high rate of radical resections and long postoperative survival.
    Marangos IP; Buanes T; Røsok BI; Kazaryan AM; Rosseland AR; Grzyb K; Villanger O; Mathisen Ø; Gladhaug IP; Edwin B
    Surgery; 2012 May; 151(5):717-23. PubMed ID: 22284762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.